Reuters Exposes Washington’s Global Disinformation Campaign: The Rest of the Story

In a recent article, Reuters confirms what many knew for years, that the United States government and its various departments and agencies have been conducting global disinformation campaigns targeting nations it seeks to undermine, and whose governments it seeks to overthrow.

Reuters Exposes Washington’s Global Disinformation Campaign: The Rest of the Story

Previously:

Philippines: Pentagon ran secret anti-vax campaign to undermine China during pandemic

Philippines: ACT solon wants to probe alleged US Pentagon secret anti-vax campaign

MANILA, Philippines — A lawmaker on Sunday called on the leaders of the House of Representatives to initiate a thorough probe into the alleged secret anti-inoculation campaign of the United States (US) military aimed at undermining China during the COVID-19 pandemic.

ACT solon wants to probe alleged US Pentagon secret anti-vax campaign (archived)

Previously:

Philippines: Pentagon ran secret anti-vax campaign to undermine China during pandemic

Journalistic Malpractice on Trial: What the Dominion Voting System Tells Us About How the Media Sacrificed their Credibility to Partisan Falsehoods

Journalistic Malpractice on Trial: What the Dominion Voting System Tells Us About How the Media Sacrificed their Credibility to Partisan Falsehoods

While the courts are unlikely to deliver solace from political party propaganda disguised as journalism, they have provided some wisdom. Both Rachel Maddow and Tucker Carlson of MSNBC and Fox News Channel respectively, have been brought to court for spreading false information and were exonerated because the judges concluded that no reasonable person would believe either of them were telling the truth. That is good advice, and viewers would be wise to remember it every time they consider watching cable news.

America’s $52 Billion Plan to Make Chips at Home Faces a Labor Shortage + manufacturing chips in the US could make smartphones more expensive

America’s $52 Billion Plan to Make Chips at Home Faces a Labor Shortage

Another possible fix would be to keep people in the workforce longer, by raising the age at which workers can begin collecting Social Security or tapping into their pensions or 401(k)s. Yet Harry Holzer, a former US Department of Labor chief economist now at Georgetown University, says that neither feels politically feasible right now. Immigration has been a toxic issue in American politics for years, and Social Security has long been an untouchable entitlement. “None of that is doable,” Holzer says, which means “our labor force growth is going to continue to be modest.”

Related:

How manufacturing chips in the US could make smartphones more expensive

Morcos says a top concern of his is the narrowness of the CHIPS Act. Without bringing related device manufacturing back to the U.S., such as device batteries, sensors, cameras, antennas, and hundreds of other components, the manufacturing process could require the most critical component to be produced stateside, then shipped overseas to be assembled with hundreds of other components into a device that is then shipped back to the U.S. for the American consumer.

Work longer, for less pay, and you still won’t be able to afford the latest smartphone or laptop?! 🤷🏼‍♀️

Brazil: More Fascism and Neocolonialism or a Path Back to Self-Determination?

By Danny Shaw,

(The author has changed certain names and details to protect individuals’ privacy.)

When you arrive in another country, there is nothing more precious than new friends who adopt you, protect you, and teach you about their language, music, culture, and traditions. For an open-minded traveler, ethnographer and anti-imperialist organizer, this new family is more valuable than any air-conditioned hotel, amount of comfort or money.

Brazil: More Fascism and Neocolonialism or a Path Back to Self-Determination?

New COVID Booster Approved From Final Study of Mice, Not Humans, But Using Only Animal Data Is a Needless Gamble

VERIFY: New COVID booster approved from final study of mice, not humans

According to documents on the CDC website, human tests of Moderna’s version of the new booster are still “ongoing.” Right now, there is only final evidence from “8-10 mice” per group.”

The FDA’s website shows for Pfizer the agency also relayed on the final study evidence from “8 mice.” But human trials are also ongoing. So far, the new boosters “showed a similar local reaction and systemic event profile.” That means side effects appear to be about the same including “mild to moderate injection site pain, fatigue, and muscle pain.”

“To advance the Omicron BA.4/BA.5 bivalent vaccine as rapidly as possible, regulators, including the FDA, WHO and EMA, have advised that our submissions be based on safety and immunogenicity data generated in adults with an Omicron BA.1 bivalent vaccine and supported by BA.4/BA.5 bivalent pre-clinical data and BA.4/BA.5 bivalent quality and manufacturing data. These packages follow a similar model to that provided to public health officials who evaluate seasonal flu vaccines each year. Moving forward, this approach may help address the pressing need for vaccines that provide a high level of protection against current and emerging variants of concern so that we can remain vigilant against this evolving virus. The FDA has authorized our Omicron BA.4/BA.5 bivalent vaccine based on clinical data generated in adults with an Omicron BA.1 bivalent vaccine, pre-clinical data with a BA.4/BA.5 bivalent vaccine and BA.4/BA.5 bivalent quality and manufacturing data. Pre-clinical data showed a booster dose of Pfizer and BioNTech’s Omicron BA.4/BA.5- bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability and immunogenicity of the Omicron BA.4/BA.5 bivalent vaccine in individuals 12 years of age and older is ongoing. Data will be shared with regulators when available. We are facing a virus with an exceptionally high mutation rate, which the nimble mRNA platform is well situated to address. Only the mRNA sequence requires updating to match emerging strains, and utilizing a bivalent vaccine aims to provide broader coverage against known and future COVID-19 variants of concern.”

Related:

Read More »